Lexeo Therapeutics
LXEO
88 hedge funds and large institutions have $100M invested in Lexeo Therapeutics in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 18 closing their positions.
28% more call options, than puts
Call options by funds: $111K | Put options by funds: $87K
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 90 → 88 (-2)
4.9% less ownership
Funds ownership: 89.26% → 84.36% (-4.9%)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
49% less capital invested
Capital invested by funds: $194M → $100M (-$94.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$6.56M |
| 2 |
Millennium Management
New York
|
+$4.12M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$2.86M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.54M |
| 5 |
Janus Henderson Group
London,
|
+$969K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.73M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.13M |
| 3 |
DCP
D1 Capital Partners
New York
|
-$5.43M |
| 4 |
ACM
Altium Capital Management
New York
|
-$2.66M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.31M |
LXEO Hedge Fund Activity: Q1 2025 in Review
88 institutional investors reported a position in Lexeo Therapeutics (LXEO) for Q1 2025, worth a combined $100M — down 49% from $194M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of LXEO and 16 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 25 added.
The largest buyer was Affinity Asset Advisors, opening a new position worth an estimated $6.56M. The largest seller was Adage Capital Partners, cutting an estimated $8.73M.
- 88 institutional investors held Lexeo Therapeutics (LXEO) as of Q1 2025, down from 90 in Q4 2024.
- Funds reported $100M of Lexeo Therapeutics stock for Q1 2025, down 49% quarter-over-quarter.
- 16 funds opened new Lexeo Therapeutics positions in Q1 2025 and 18 closed out, a net change of -2 holders.
- The largest Lexeo Therapeutics buyer in Q1 2025 was Affinity Asset Advisors, an estimated $6.56M added.
- The largest Lexeo Therapeutics seller in Q1 2025 was Adage Capital Partners, an estimated $8.73M sold.
Based on aggregated 13F filings for Q1 2025.